Exenatide (Byetta®): Incretinomimetic in the treatment of type 2 diabetes after failure and as add-on therapy to oral agents;Le médicament du mois: Exénatide (Byetta®) - Incrétinomimétique indiqué dans le traitement du diabète de type 2 après échec et en complément des antidiabétiques oraux

Revue Medicale de Liege

Volumn 63, Issue 3, 2008, Pages 158-165

  Scheen, A J ^a,b   Van Gaal, L F ^c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c Hôpital Universitaire d'Anvers

Author keywords

Exenatide; Glucagon like peptide 1; Incretin; Insulin secretion; Type 2 diabetes

Indexed keywords

EXENDIN 4; INSULIN; METFORMIN; SULFONYLUREA;

BLOOD GLUCOSE MONITORING; DRUG DOSE TITRATION; DRUG TOLERABILITY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; TREATMENT FAILURE;

DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES; VENOMS;

EID: 41749085260     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Féry F, Paquot N. - Etiopathogénie et Physiopathologie du diabète de type 2. Rev Med Liège, 2005, 60, 361-368.
2. Scheen AJ, Radermecker RP, Philips JC, et al. - Le traitement du diabète de type 2 : entre insulinosensibilisateurs et insulinosécrétagogues. Rev Med Liège, 2007, 62, (numéro spécial), 40-46.
3. Van Gaal LF, De Leeuw I. - Rationale and options for combination therapy in the treatment of type 2 diabetes. Diabetologia, 2003, 46 (Suppl 1), M44-M50.
4. Nathan DM, Buse JB, Davidson MB, et al. - Management of hyperglycaemia in type 2 diabetes : a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2006, 49, 1711-1721 (Update regarding the thiazolidinediones. Diabetologia, 2008, 51, 8-11).
5. American Diabetes Association. - Standards of medical care in diabetes - 2008. Diabetes Care, 2008, 31 (Suppl 1), S12-54.
6. Scheen AJ. - L'indication de l'insulinothérapie dans le diabète de type 2. Médecine Clinique Endocrinologie & Diabète, 2005, No Hors série «Insuline lente», 2-5.
7. Kerr D, Cavan D. - Treating obese patients with poorly controlled diabetes : confessions of an insulin therapist. Diabetes Metab Res Rev, 1999, 15, 219-225.
8. Scheen AJ, Van Gaal LF. - Le diabète de type 2 au coeur du syndrome métabolique : plaidoyer pour une prise en charge globale. Rev Med Liège, 2005, 60, 566-571.
9. Van Gaal LF, Mertens IL, De Block CE. - Mechanisms linking obesity with cardiovascular disease. Nature, 2006, 444, 875-880.
10. Scheen AJ, Van Gaal LF. - Rimonabant (Acomplia®). Premier antagoniste des récepteurs CB1 du système endocannabinoïde. Rev Med Liège, 2008, 63, 50-55.
11. Drucker DJ, Nauck MA. - The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 2006, 368, 1696-1705.
12. Scheen AJ, Radermecker RP, Philips JC, Paquot N. - Les incrétinomimétiques et incrétinopotentiateurs dans le traitement du diabète de type 2. Rev Med Suisse, 2007, 3, 1884-1888.
13. Scheen AJ. - Le glucagon-like peptide-1 (GLP-1), nouvelle cible dans le traitement du diabète de type 2. Rev Med Liège, 2007, 62, 216-219.
14. Wajchenberg BL. - Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev, 2007, 28, 187-218.
15. Scheen AJ, Van Gaal LF. - Sitagliptine (Januvia®). Incrétinopotentiateur indiqué comme insulinosécré tagogue dans le traitement du diabète de type 2. Rev Med Liège, 2008, 63, 105-109.
16. Eli Lilly Exenatide summary of product characteristics. 2007. Available at http://www.emea;Europa;eu/human-docs/PDFs/EPAR/byetta/H-698-PI-en.pdf. Accessed January 15, 2008.
17. Nielsen LL, Young AA, Parkes DG. - Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept, 2004, 117, 77-88.
18. Kolterman OG, Buse JB, Fineman MS, et al. - Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab, 2003, 88, 3082-3089.
19. Fehse F, Trautman M, Hoist JJ, et al. - Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab, 2005, 90, 5991-5997.
20. Degn KB, Brock B, Juhl CB, et al. - Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes, 2004, 53, 2397-2403.
21. Kim D, MacConell LM, Zhuang D, et al. - Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care, 2007, 30, 1487-1493.
22. Linnebjerg H, Kothare PA, Park S, et al. - Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol, 2007, 64, 317-327.
23. De Fronzo RA, Ratner RE, Han J, et al. - Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care, 2005, 28, 1092-1100.
24. Buse JB, Henry RR, Han J, et al. - Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care, 2004, 27, 2628-2635.
25. Kendall DM, Riddle MC, Rosenstock J, et al. - Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care, 2005, 28, 1083-1091.
26. Zinman B, Hoogwerf BJ, Garcia SD, et al. - The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. A randomized trial. Ann Intern Med, 2007, 146, 477-485.
27. Amori RE, Lau J, Pittas AG, et al. - Efficacy and safety of incretin therapy in type 2 diabetes : systematic review and meta-analysis. JAMA, 2007, 298, 194-206.
28. Buse JB, Klonoff DC, Nielsen LL, et al. - Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes : an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther, 2007, 29, 139-153.
29. Klonoff DC; Buse JB, Nielsen LL, et al. - Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin, 2008, 24, 275-286.
30. Van Gaal LF, Gutkin SW, Nauck MA. - Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists or insulin for patients with inadequate glycemic control? Eur J Endocrinol, 2008, in press.
31. Heine RJ, Van Gaal LF, Johns D, et al. - Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. A randomized trial. Ann Intern Med, 2005, 143, 559-569.
32. Barnett AH, Burger J, Johns D, et al. - Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea : a multinational, randomized, open-label, two-period crossover noninferiority trial. Clin Ther, 2007, 29, 2333-2348.
33. Nauck MA, Duran S, Kim D, et al. - A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia, 2007, 50, 259-267.
34. Glass LC, Qu Y, Lenox S, et al. - Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes : a pooled post-hoc analysis. Curr Med Res Opin, 2008, 24, 639-644.
35. Davis SN, Johns D, Maggs D, et al. - Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care, 2007, 30, 2767-2772.
36. Cvetkovic RS, Plosker GL. - Exenatide : a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs, 2007, 67, 935-954.